Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Business Officer | March 01, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,700 |
Reported balance
After 2023-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 10,557 · Balance 19,700 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. F2: This number includes 465 shares acquired under the Registrant's employee stock purchase plan (the "ESPP") on June 1, 2022 and 1,678 shares acquired under the ESPP on December 1, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 19,150 |
Reported balance
After 2023-03-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-02 · Sale · Disposed 550 · Balance 19,150 F3: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 18,986 |
Reported balance
After 2023-03-02 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-03-02 · Sale · Disposed 164 · Balance 18,986 F3: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.07 · Expires 2033-02-28 | Direct | 63,338 |
Reported balance
After 2023-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-01 · Grant · Acquired 63,338 · Balance 63,338 F6: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
F2: This number includes 465 shares acquired under the Registrant's employee stock purchase plan (the "ESPP") on June 1, 2022 and 1,678 shares acquired under the ESPP on December 1, 2022.
F3: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2023 Filed Mar 3, 2023 21:31 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 164 | $31.40 | $5,149.16 |
DisclosureSEC source: 0000899243-23-006984 · doc4.xml · nonDerivative · entry 3 Caughey Elaine · CIK 0001868668 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,986 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:31 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 550 | $30.88 | $16,982.57 |
DisclosureSEC source: 0000899243-23-006984 · doc4.xml · nonDerivative · entry 2 Caughey Elaine · CIK 0001868668 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,150 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 63,338 | $0.00 Strike: $32.07 | $0.00 |
DisclosureSEC source: 0000899243-23-006984 · doc4.xml · derivative · entry 4 Caughey Elaine · CIK 0001868668 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,338 Underlying: Common Stock · 63,338 shares Expires 2033-02-28 F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 10,557 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006984 · doc4.xml · nonDerivative · entry 1 Caughey Elaine · CIK 0001868668 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,700 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. F2 · balance_after: This number includes 465 shares acquired under the Registrant's employee stock purchase plan (the "ESPP") on June 1, 2022 and 1,678 shares acquired under the ESPP on December 1, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 41,000 | $0.00 Strike: $38.53 | $0.00 |
DisclosureSEC source: 0000899243-22-009074 · doc4.xml · derivative · entry 2 Caughey Elaine · CIK 0001868668 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2032-02-29 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009074 · doc4.xml · nonDerivative · entry 1 Caughey Elaine · CIK 0001868668 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 21, 2021 Filed Jun 21, 2021 21:36 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0000899243-21-025048 · doc4.xml · derivative · entry 1 Caughey Elaine · CIK 0001868668 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-20 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option shall vest on June 21, 2022, and the remainder shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.